1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Genentech withdraws psoriasis drug Raptiva in US over PML risk

 
• By Katie McQue

Genentech is to withdraw its psoriasis therapy Raptiva (efalizumab) in the US based on its association with an increased risk of developing progressive multifocal leucoencephalopathy (PML), a rare and potentially fatal brain infection.

Genentech is to withdraw its psoriasis therapy Raptiva (efalizumab) in the US based on its association with an increased risk of developing progressive multifocal leucoencephalopathy (PML), a rare and potentially fatal brain infection.

Three patients taking the monoclonal antibody therapy were diagnosed with cases of PML, two of which were fatal. A fourth...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapeutic Category

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 
• By Andrew McConaghie

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.